Last quarter (Q3 2024), Travere Therapeutics's total revenue was $62.90M, an increase of 69.56% from the same quarter last year. In Q3, Travere Therapeutics's net income was $-54.81M. See Travere Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 203.45M	$ 145.24M	$ 109.46M	$ 131.84M	$ 198.32M	$ 175.34M
Cost of Revenue	$ 9.76M	$ 11.45M	$ 4.42M	$ 3.82M	$ 6.13M	$ 5.23M
Gross Profit	$ 193.69M	$ 133.79M	$ 105.04M	$ 128.02M	$ 192.19M	$ 170.10M
Operating Expense	$ 456.58M	$ 510.53M	$ 424.85M	$ 360.21M	$ 364.70M	$ 269.91M
Operating Income	$ -384.02M	$ -388.14M	$ -319.81M	$ -161.76M	$ -176.16M	$ -137.36M
Net Non Operating Interest Income Expense	$ 15.71M	$ 10.43M	$ 4.74M	$ -18.15M	$ -14.05M	$ -8.74M
Other Income Expense	$ -6.84M	$ -9.80M	$ -6.60M	$ -231.00K	$ -1.42M	$ 15.31M
Pretax Income	$ -375.23M	$ -376.11M	$ -331.15M	$ -179.68M	$ -188.79M	$ -146.45M
Tax Provision	$ 260.00K	$ 223.00K	$ 313.00K	$ 409.00K	$ -19.36M	$ -21.00K
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ -351.45M	$ -111.40M	$ -278.48M	$ -180.09M	$ -169.43M	$ -152.30M
Basic EPS	$ -4.44	$ -1.50	$ -4.37	$ -3.01	$ -3.56	$ -3.46
Diluted EPS	$ -4.44	$ -1.50	$ -4.37	$ -3.01	$ -3.56	$ -3.46
Basic Average Shares	$ 309.00M	$ 74.27M	$ 63.76M	$ 59.83M	$ 47.54M	$ 42.34M
Diluted Average Shares	$ 309.00M	$ 74.27M	$ 63.76M	$ 59.83M	$ ―	$ 42.34M
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ 469.84M	$ 521.98M	$ 429.27M	$ 367.00M	$ 370.83M	$ 275.15M
Net Income From Continuing And Discontinued Operation	$ -351.45M	$ -111.40M	$ -278.48M	$ -180.09M	$ -169.43M	$ -146.43M
Normalized Income	$ -202.82M	$ -282.33M	$ ―	$ ―	$ ―	$ ―
Interest Expense	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
EBIT	$ -275.08M	$ -364.78M	$ -320.14M	$ -197.20M	$ -169.74M	$ -127.65M
EBITDA	$ -234.13M	$ -326.25M	$ -299.42M	$ -184.46M	$ -145.16M	$ -98.07M

Currency in USD

Travere Therapeutics Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing